Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MOLN
- Price
- 3.57
- Stock movement down
- -0.34 (-8.70%)
- Company name
- Molecular Partners AG ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 131.60M
- Ent value
- 81.28M
- Price/Sales
- 21.93
- Price/Book
- 0.95
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 1.57%
- 1 year return
- -9.62%
- 3 year return
- -44.09%
- 5 year return
- -27.35%
- 10 year return
- -18.01%
Last updated: 2025-04-17
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MOLN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 21.93 |
| Price to Book | 0.95 |
| EV to Sales | 13.54 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 36.86M |
| EPS (TTM) | -1.89 |
| FCF per share (TTM) | -1.82 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 6.00M |
| Gross profit (TTM) | -33.10M |
| Operating income (TTM) | -63.07M |
| Net income (TTM) | -62.59M |
| EPS (TTM) | -1.89 |
| EPS (1y forward) | -1.64 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -551.47% |
| Operating margin (TTM) | -1050.83% |
| Profit margin (TTM) | -1042.84% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 65.75M |
| Net receivables | 3.32M |
| Total current assets | 149.53M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 154.21M |
| Accounts payable | 2.38M |
| Short/Current long term debt | 2.75M |
| Total current liabilities | 10.44M |
| Total liabilities | 15.43M |
| Shareholder's equity | 138.78M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -59.66M |
| Capital expenditures (TTM) | 896.00K |
| Free cash flow (TTM) | -60.55M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -45.10% |
| Return on Assets | -40.59% |
| Return on Invested Capital | -44.71% |
| Cash Return on Invested Capital | -43.25% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.86 |
| Daily high | 3.90 |
| Daily low | 3.57 |
| Daily Volume | 2K |
| All-time high | 38.40 |
| 1y analyst estimate | 10.45 |
| Beta | 0.54 |
| EPS (TTM) | -1.89 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 17 Apr 2025 |
Downside potential
Loading...
Downside potential data
| MOLN | S&P500 | |
| Current price drop from All-time high | -90.70% | -14.24% |
| Highest price drop | -91.35% | -56.47% |
| Date of highest drop | 19 Apr 2024 | 9 Mar 2009 |
| Avg drop from high | -51.22% | -11.07% |
| Avg time to new high | 119 days | 12 days |
| Max time to new high | 2369 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
131.60M
Marketcap category
Small-cap
Description
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Employees
167
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page